Y
Yoshikazu Inoue
Researcher at Cincinnati Children's Hospital Medical Center
Publications - 273
Citations - 17662
Yoshikazu Inoue is an academic researcher from Cincinnati Children's Hospital Medical Center. The author has contributed to research in topics: Idiopathic pulmonary fibrosis & Medicine. The author has an hindex of 48, co-authored 233 publications receiving 12648 citations. Previous affiliations of Yoshikazu Inoue include Niigata University.
Papers
More filters
Journal ArticleDOI
Responsiveness and meaningful change thresholds of the Living with Pulmonary Fibrosis (L-PF) questionnaire Dyspnoea and Cough scores in patients with progressive fibrosing interstitial lung diseases
Jeffrey J. Swigris,Donald M. Bushnell,Klaus B. Rohr,Heiko Mueller,Michael Baldwin,Yoshikazu Inoue +5 more
TL;DR: These analyses support the responsiveness, one aspect of validity, of the L-PF Dyspnoea and Cough domains scores as measures of symptom severity in patients with progressive fibrosing ILDs.
Journal ArticleDOI
Diagnostic yield and safety of bronchofiberscopy for pulmonary alveolar proteinosis.
Koji Azuma,Takayuki Takimoto,Takahiko Kasai,Masaki Hirose,Kazuyoshi Hatsuda,Chikatoshi Sugimoto,Toru Arai,Masanori Akira,Yoshikazu Inoue +8 more
TL;DR: In this article, the authors examined 86 patients who underwent bronchofiberscopy with bronchoalveolar lavage (BAL) and transbronchial lung forceps biopsy (TBLB).
Journal ArticleDOI
Is corticosteroid use truly not associated with improved outcomes in AE-IPF?
Toru Arai,Yoshikazu Inoue +1 more
TL;DR: In this article, the authors present a survey of the state of the art in bioinformatics, and propose a solution.See Reply.See also: http://www.
Journal ArticleDOI
A comorbid case of multicentric Castleman's disease and pulmonary hyalinising granuloma successfully treated with tocilizumab and corticosteroid
TL;DR: A 49-year-old man with superficial lymphadenopathy presented with symptoms of low-grade fever, general fatigue and weight loss and was diagnosed with multicentric Castleman's disease complicated by pulmonary hyalinising granulomas; his symptoms improved by treatment with tocilizumab, which is a humanised antihuman IL-6 receptor monoclonal antibody and corticosteroid.
Journal ArticleDOI
Seroradiologic prognostic evaluation of acute exacerbation in patients with idiopathic interstitial pneumonia: a retrospective observational study.
Toru Arai,Masanori Akira,Chikatoshi Sugimoto,Kazunobu Tachibana,Yasushi Inoue,Sayoko Shintani,Tomohisa Okuma,Takahiko Kasai,Seiji Hayashi,Yoshikazu Inoue +9 more
TL;DR: Combining the HRCT pattern and the ΔKL-6/ST-Kl-6 value can improve the ability to predict the survival of AE-IIP patients.